Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
Testimony of BIO President & CEO John F. Crowley…
Chairman Cassidy, Ranking Member Sanders, and distinguished Members of the Committee:Thank you for the opportunity to appear before you today on behalf of the Biotechnology Innovation Organization (BIO), which represents more than 1,000…
Learn more
BIO Statement on Vaccines and Autism
Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…
Learn more
BIO's Comments to CDC’s Advisory Committee on…
Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
BIO letter in support of H.R. 5418
March 10, 2016
To establish a pilot program for educating district court judges on patent related issues.
Cures Acceleration Network: Legislative Text
March 10, 2016
The Cures Acceleration Network, passed in the recently enacted healthcare reform bill, will provide funding to public and private entities to bridge the gap between basic research and cures for patients.
Small Business Early Stage Investment Program: Legislative Text
March 10, 2016
The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.
BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill
March 10, 2016
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA…
Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008
March 10, 2016
Global Health Challenges: How Industry is Addressing Global Health
Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal
March 10, 2016
Government's role in developing solutions for diseases that disproportionately affect developing countries
Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)
March 10, 2016
Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA
Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA
March 10, 2016
Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE
Eileen Yen, former Director, Sarawak Biodiversity Centre, Malaysia
March 10, 2016
The Patent Reform Act of 2007 - Coalition Letter
March 10, 2016
More than 430 organizations representing American innovation in a wide range of industries in all 50 states wrote Senate leaders to express continued concern with S. 1145.